<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Exemestane: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Exemestane: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Exemestane: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12459" href="/d/html/12459.html" rel="external">see "Exemestane: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F169505"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aromasin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866861"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Exemestane;</li>
<li>Aromasin;</li>
<li>MED-Exemestane;</li>
<li>TEVA-Exemestane</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F169523"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Aromatase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F169508"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f11018ba-205d-4754-ac29-da77a4af9d90">Breast cancer, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, adjuvant therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant treatment following 2 to 3 years of tamoxifen:</i> Postmenopausal patients: <b>Oral:</b> 25 mg once daily (following 2 to 3 years of tamoxifen therapy) for a total duration of 5 years of endocrine therapy (in the absence of recurrence or contralateral breast cancer).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>First-line adjuvant treatment (off-label use):</i> Postmenopausal patients: <b>Oral:</b> 25 mg once daily for 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20625130','lexi-content-ref-21247627']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20625130','lexi-content-ref-21247627'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant endocrine therapy (in combination with ovarian function suppression) for hormone receptor–positive high-risk disease (off-label use):</i> Premenopausal patients: <b>Oral:</b> 25 mg once daily (in combination with ovarian function suppression [OFS]) for ~5 years; if chemotherapy was administered, initiate exemestane after chemotherapy completion, and, if chemotherapy was not administered, initiate exemestane 6 to 8 weeks after OFS initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24881463']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24881463'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of adjuvant endocrine therapy:</i> American Society of Clinical Oncology (ASCO) guidelines for adjuvant endocrine therapy for women with hormone receptor<i>–</i>positive (HR+) breast cancer (focused update) recommend a duration of 5 to 10 years of adjuvant endocrine therapy; some patients may be appropriate candidates for extended aromatase inhibitor (AI) therapy for up to a total of 10 years based on disease recurrence risk and nodal disease status. Refer to the guidelines for specific recommendations based on menopausal status and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30452337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30452337'])">Ref</a></span>). In a phase 3 study with another AI (letrozole), treatment with an additional 5 years of AI therapy (for a total of 10 years of endocrine therapy) demonstrated a significantly improved rate of disease-free survival and a decreased risk of disease recurrence and contralateral breast cancer (when compared to placebo); although, overall survival was not significantly different between groups, and bone-related adverse events occurred more frequently with letrozole versus placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27264120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27264120'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70f72d8d-3f95-478a-a281-8d0e7521cd98">Breast cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced:</b> Postmenopausal patients: <b>Oral:</b> 25 mg once daily; continue until tumor progression.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label combination:</i> Breast cancer, hormone receptor<i>–</i>positive (HR+), advanced, in patients with recurrence or progression on prior endocrine therapy: Postmenopausal patients: <b>Oral:</b> 25 mg once daily (in combination with everolimus) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22149876']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22149876'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The ASCO guideline update for endocrine treatment and targeted therapy for HR+, human epidermal growth factor receptor 2-negative metastatic breast cancer supports the use of an AI in combination with a CDK4/6 inhibitor for the initial treatment of HR+ metastatic breast cancer in postmenopausal patients, and in premenopausal patients when combined with chemical ovarian function suppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34324367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34324367'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef12445f-5450-4468-80d0-329501655968">Breast cancer in male patients, hormone receptor–positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer in male patients, hormone receptor<i>–</i>positive (off-label use): Note: </b>Should be used in combination with a gonadotropin-releasing hormone agonist/antagonist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant therapy (alternative agent):</i> May be used as adjuvant therapy in male patients with HR+ breast cancer with a contraindication to tamoxifen. <b>Oral:</b> 25 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33538790']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33538790'])">Ref</a></span>). ASCO guidelines for management of male breast cancer recommend an initial duration of 5 years of adjuvant endocrine therapy; if there still is a high risk of recurrence, 5 additional years of endocrine therapy may be offered if the initial 5 years of adjuvant therapy have been completed and tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Advanced or metastatic disease:</i>
<b> Oral:</b> 25 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33538790','lexi-content-ref-23722469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33538790','lexi-content-ref-23722469'])">Ref</a></span>). Endocrine therapy for males with advanced or metastatic, HR+, HER2-negative breast cancer may be sequenced as in females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89d22de8-e4a8-41ee-83bc-1e4e83706316">Breast cancer, risk reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, risk reduction (off-label use):</b> Postmenopausal patients ≥35 years of age at increased risk of developing breast cancer: <b>Oral:</b> 25 mg once daily for 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31479306','lexi-content-ref-21639806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31479306','lexi-content-ref-21639806'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990258"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No adjustment necessary (although the safety of chronic doses in patients with moderate-to-severe renal impairment has not been studied, dosage adjustment does not appear necessary). </p></div>
<div class="block doha drugH1Div" id="F50987424"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No adjustment necessary (although the safety of chronic doses in patients with moderate-to-severe hepatic impairment has not been studied, dosage adjustment does not appear necessary).</p></div>
<div class="block dot drugH1Div" id="F56516479"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Decreased bone mineral density: Manage bone density loss as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D deficiency: Supplement as clinically indicated.</p></div>
<div class="block doe drugH1Div" id="F169509"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F169477"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (5% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (15%), hyperhidrosis (4% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (13% to 33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (9% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocytopenia (grades 3/4: 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (14% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (6% to 13%), fatigue (8% to 22%), headache (7% to 13%), insomnia (11% to 12%), pain (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (≤2%), angina pectoris (≤2%), chest pain (2% to 5%), edema (≤7%), ischemic heart disease (≤2%), lower extremity edema (≤7%), peripheral edema (≤7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (8%), pruritus (2% to 5%), skin rash (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase (grades 3/4: 3%), weight gain (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (6%), anorexia (6%), constipation (5%), diarrhea (4% to 10%), dyspepsia (2% to 5%), increased appetite (3%), vomiting (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphedema (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (5% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (10%), carpal tunnel syndrome (2%), confusion (2% to 5%), dizziness (8% to 10%), hypoesthesia (2% to 5%), paresthesia (3%), tumor pain (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (6%), back pain (9%), limb pain (9%), muscle cramps (2%), myalgia (6%), osteoarthritis (6%), osteoporosis (5%), pathological fracture (4%), skeletal pain (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (2% to 5%), cough (6%), dyspnea (10%), flu-like symptoms (6%), pharyngitis (2% to 5%), rhinitis (2% to 5%), sinusitis (2% to 5%), upper respiratory tract infection (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure, thromboembolism</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastric ulcer</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Endometrial hyperplasia, endometrial polyps</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Abnormal bone growth (osteochondrosis), tenosynovitis (stenosans [trigger finger])</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased bone mineral density</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis, hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F169489"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to exemestane or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F169474"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Decreased bone mineral density: Due to decreased circulating estrogen levels, exemestane is associated with a reduction in bone mineral density over time. Decreases (from baseline) in lumbar spine and femoral neck density have been observed (when compared to tamoxifen or placebo in studies where concomitant use of bisphosphonates, calcium and vitamin D were not allowed).</p>
<p style="text-indent:-2em;margin-left:4em;">• Lymphopenia: Grade 3 or 4 lymphopenia has been observed with exemestane, although most patients had preexisting lower grade lymphopenia; some patients improved or recovered while continuing exemestane. Lymphopenia did not result in a significant increase in viral infections, and no opportunistic infections were observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lab parameters: Elevations of AST, ALT, alkaline phosphatase, and gamma glutamyl transferase &gt;5 times ULN have been observed (rarely) in patients with advanced breast cancer; may be attributable to underlying liver and/or bone metastases. In patients with early breast cancer, elevations of bilirubin, alkaline phosphatase, and serum creatinine were more common with exemestane treatment than with tamoxifen or placebo.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Estrogen-containing drugs: Exemestane should not be administered concurrently with estrogen-containing medications.</p></div>
<div class="block foc drugH1Div" id="F169484"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aromasin: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg</p></div>
<div class="block geq drugH1Div" id="F169470"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F169491"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Aromasin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $46.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Exemestane Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $3.60 - $20.23</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866862"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aromasin: 25 mg [contains methyl hydroxybenzoate, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg</p></div>
<div class="block adm drugH1Div" id="F1954090"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer after a meal.</p></div>
<div class="block hazard drugH1Div" id="F49104519"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F169485"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adjuvant treatment of estrogen receptor–positive early breast cancer in postmenopausal patients who have received 2 to 3 years of tamoxifen (for completion of a total of 5 consecutive years of adjuvant hormonal therapy).</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of advanced breast cancer in postmenopausal patients whose disease has progressed following tamoxifen therapy.</p></div>
<div class="block off-label drugH1Div" id="F25474619"><span class="drugH1">Use: Off-Label: Adult</span><p>Breast cancer, high-risk, hormone receptor–positive, adjuvant endocrine therapy (in combination with ovarian function suppression) in premenopausal patients; Breast cancer, early, estrogen receptor–positive, first-line adjuvant treatment in postmenopausal patients; Breast cancer in male patients, hormone receptor–positive; Risk reduction for invasive breast cancer in postmenopausal patients</p></div>
<div class="block mst drugH1Div" id="F4091418"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aromasin may be confused with Arimidex</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Exemestane may be confused with estramustine.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F169518"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F169479"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Exemestane.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Exemestane. Management: Increase the exemestane dose to 50 mg once daily in patients receiving concurrent strong CYP3A4 inducers. Monitor patients closely for evidence of toxicity or inadequate clinical response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May diminish the therapeutic effect of Exemestane.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: Aromatase Inhibitors may increase the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Aromatase Inhibitors may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Exemestane. Management: Increase the exemestane dose to 50 mg once daily in patients receiving St John's wort. Monitor patients closely for evidence of toxicity or inadequate clinical response.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F169501"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">AUC and C<sub>max</sub> were increased by 59% and 39%, respectively, when exemestane was administered with a high-fat breakfast. Management: Administer after a meal.</p></div>
<div class="block rep_considerations drugH1Div" id="F49306365"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Pregnancy testing within 7 days prior to initiation of exemestane is recommended for patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment and for 1 month after the final exemestane dose.</p></div>
<div class="block pri drugH1Div" id="F169492"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action and data from animal reproduction studies, exemestane is expected to cause fetal harm if administered to a pregnant patient.</p></div>
<div class="block brc drugH1Div" id="F20617117"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if exemestane is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 1 month after the final exemestane dose.</p></div>
<div class="block mop drugH1Div" id="F16249401"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">25-hydroxy vitamin D levels (at baseline). Assess bone mineral density at baseline in patients with, or at risk for osteoporosis; monitor for bone density loss during exemestane therapy. Pregnancy testing within 7 days prior to initiation for patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Cardiovascular monitoring for patients with breast cancer: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking; estimate 10-year cardiovascular disease risk in patients without cardiovascular disease at baseline; assess cardiovascular risk annually in patients with a high 10-year risk (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F169473"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Exemestane is an irreversible, steroidal aromatase inactivator. It is structurally related to androstenedione, and is converted to an intermediate that irreversibly blocks the active site of the aromatase enzyme, leading to inactivation ("suicide inhibition") and thus preventing conversion of androgens to estrogens in peripheral tissues. Significantly lowers circulating estrogens in postmenopausal breast cancers where growth is estrogen-dependent.</p></div>
<div class="block phk drugH1Div" id="F169488"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and moderate (~42%) following oral administration; AUC and C<sub>max</sub> increased by 59% and 39%, respectively, following a high-fat breakfast (compared to fasted state).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Extensive into tissues.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 90%, primarily to albumin and α<sub>1</sub>-acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic; oxidation (CYP3A4) of methylene group, reduction of 17-keto group with formation of many secondary metabolites; metabolites are inactive.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Patients with breast cancer: 1.2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;1% as unchanged drug, 39% to 45% as metabolites); feces (36% to 48%).</p></div>
<div class="block phksp drugH1Div" id="F51154123"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC was ~3 times higher in those with moderate or severe renal impairment compared to subjects with normal renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC was ~3 times higher in those with moderate or severe hepatic impairment compared to subjects with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F169493"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Noxetol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Exemestan accord | Exemestan ratiopharm</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Estamane | Exaccord | Exemestane Ga | Exemestane gh | Exemestane sandoz</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Epsilonextane | Exemarom | Exemestan sandoz | Exemestane accord | Exemestane mylan | Exemestane pfizer | Exemestane teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alnair | Cleopa | Escepran | Exemecon | Xanepra</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Emah | Exemestano</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Aromasin | Exemestan devatis | Exemestan Mylan | Exemestan sandoz</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Exevitae</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A nuo xin | Ke yi | Su lai | Yi si tan | You ke yi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aromasin | Brestex | Exemestano | Exemestin | Tugem</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aromasin | Astexana | Escepran | Exemestan Actavis | Exemestan Mylan | Exemestan teva | Exemestane accord | Exemestane Glenmark | Exestea</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aromasin | Exemed | Exemedac | Exemestan | Exemestan accord | Exemestan Actavis | Exemestan AL | Exemestan Beta | Exemestan Biomo | Exemestan Cell Pharm | Exemestan CT | Exemestan devatis | Exemestan Dura | Exemestan Hexal | Exemestan Hormosan | Exemestan puren | Exemestan ratiopharm | Exemestan Stada | Exemestan Winthrop | Exemestane Fair Med Healthcare | Exestan | Ribostan</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Aromasin | Exemestano</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Escepran | Exemestane accord | Exemestane alvogen | Exemestane sanoswiss | Exemestane teva | Exemestane zentiva</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Aromasin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Exemestano accord | Exemestano apotex | Exemestano Cinfa | Exemestano desgen | Exemestano Kern pharma | Exemestano Mylan Pharmaceuticals | Exemestano Normon | Exemestano Ratiopharm | Exemestano sandoz | Exemestano stada | Exemestano teva | Exemestano Urquima | Exemestano vir | Exemestano zentiva</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Exemestan accord | Exemestan ratiopharm | Exemestane accord | Exemestane Arrow | Xemestan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Exemestane accord | Exemestane Actavis | Exemestane Arrow | Exemestane bgr | Exemestane Biogaran | Exemestane cristers | Exemestane EG | Exemestane mylan | Exemestane ranbaxy | Exemestane Ratio | Exemestane sandoz | Exemestane teva | Exemestane winthrop</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aromestan | Exemesin | Exemestane genepharma | Exemestane specifar | Exemestane/nexus | Exemestane/teva | Stanexem</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Aromasin | Brestan | Eksemestan jgl | Peramit</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Etadron | Exemestan teva | Exemestane Medico Uno | Exemestane pharmacenter | Exemin | Funamel | Mexezon | Tearan</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Aromasin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Exemestane Actavis | Exemestane teva</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Aromasin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aromasin | Exetraz | Samexa | Xcel | Xtane</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Exemestane Accord Healthcare | Exemestane Actavis | Exemestane Doc | Exemestane mylan | Exemestane pharos generics | Exemestane sandoz | Exemestane teva | Exemestane zentiva | Memelin | Mestane | Naxestan | Nibestan</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Aromasin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Exemestane teva</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Aromasin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aromasin | Exemestane Arrow | Exemestane genepharm | Orapec</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Arostanil | Escepran | Exemestane accord | Exemestane alvogen | Exemestane sanoswiss | Exemestane teva</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Exemarom | Exemestan ratiopharm | Exemestan sandoz</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Escepran | Exemestane accord | Exemestane alvogen | Exemestane sanoswiss | Exemestane teva</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Exemestane Normon | Exemestane zenith</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bikipen | Dixixifatil | Exinnocam | Ixenemi | Tertrovan | Xenq | Zurimacin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Exetas</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Aromasin | Exemestaan | Exemestaan Accord | Exemestaan Actavis | Exemestaan CF | Exemestaan Mylan | Exemestaan Pfizer | Exemestaan Sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Exemestan sandoz</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Exemestane pfizer</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Exetas</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Arostanil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Exetu | Ph&amp;t exemestane | Xemest | Xtane</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aromasin | Cotamox | Etadron | Glandex | Symex</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Aromasin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Aromasin | Exemestano | Exemestano accord | Exemestano hikma | Exemestano sandoz</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aromasin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Escepran | Exemestan accord | Exemestan Actavis | Exemestan Alvogen | Exemestan Glenmark | Exemestan Polisano | Exemestan teva | Exestralan | Inplavia | Xanepra</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aromasin | Aromeston | Exemestane teva | Exemestane tl</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ezoloc</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Exemestan 2care4 | Exemestan abacus medicine | Exemestan ebb | Exemestan sandoz | Exemestane accord | Exemestane Arrow | Exemestane teva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Exemestane stada</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Astexana | Cotamox | Escepran | Exemestan Mylan | Exemestan Stada | Exemestan teva | Exemestane accord | Exemestane Glenmark | Exemestane pharmacenter | Exemestane pharos generics | Exestea</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Aromaplex | Exemestane genepha</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Exetu | Femmex</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Aromastan | Eksemarin | Exemestane grindeks | Exemevista</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Aromasin | Exemestano</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Actamasin | Aspen exemestane | Equisin | Exican</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USPNF.1">
<a name="USPNF.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aromasin.1">
<a name="Aromasin.1"></a>Aromasin (exemestane) [prescribing information]. New York, NY: Pfizer; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22149876">
<a name="22149876"></a>Baselga J, Campone M, Piccart M, et al. Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. <i>N Engl J Med</i>. 2012;366(6):520-529. doi:10.1056/NEJMoa1109653<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/22149876/pubmed" id="22149876" target="_blank">22149876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26729437">
<a name="26729437"></a>Bellet M, Gray KP, Francis PA, et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the Suppression of Ovarian Function Trial (SOFT): the SOFT-EST Substudy. <i>J Clin Oncol.</i> 2016;34(14):1584-1593. doi:10.1200/JCO.2015.61.2259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/26729437/pubmed" id="26729437" target="_blank">26729437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19717534">
<a name="19717534"></a>Bertelli G, Hall E, Ireland E, et al. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES) -- A randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. <i>Ann Oncol,</i> 2010;21(3):498-505.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/19717534/pubmed" id="19717534" target="_blank">19717534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30452337">
<a name="30452337"></a>Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. <i>J Clin Oncol.</i> 2019;37(5):423-438. doi:10.1200/JCO.18.01160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/30452337/pubmed" id="30452337" target="_blank">30452337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26884586">
<a name="26884586"></a>Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline update on ovarian suppression. <i>J Clin Oncol.</i> 2016;34(14):1689-1701. doi:10.1200/JCO.2015.65.9573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/26884586/pubmed" id="26884586" target="_blank">26884586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20625130">
<a name="20625130"></a>Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology Clinical Practice Guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. <i>J Clin Oncol</i>. 2010;28(23):3784-3796. doi:10.1200/JCO.2009.26.3756<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/20625130/pubmed" id="20625130" target="_blank">20625130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34324367">
<a name="34324367"></a>Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(35):3959-3977. doi:10.1200/JCO.21.01392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/34324367/pubmed" id="34324367" target="_blank">34324367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29863451">
<a name="29863451"></a>Francis PA, Pagani O, Fleming G, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. <i>N Engl J Med. </i>2018;379(2):122-137. doi:10.1056/NEJMoa1803164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/29863451/pubmed" id="29863451" target="_blank">29863451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21639806">
<a name="21639806"></a>Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. <i>N Engl J Med</i>. 2011;364(25):2381-2391.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/21639806/pubmed" id="21639806" target="_blank">21639806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23358971">
<a name="23358971"></a>Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. <i>J Clin Oncol</i>. 2013;31(11):1398-1404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/23358971/pubmed" id="23358971" target="_blank">23358971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27264120">
<a name="27264120"></a>Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years.<i> N Engl J Med</i>. 2016;375(3):209-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/27264120/pubmed" id="27264120" target="_blank">27264120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058842">
<a name="32058842"></a>Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(16):1849-1863. doi:10.1200/JCO.19.03120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/32058842/pubmed" id="32058842" target="_blank">32058842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).<i> Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24881463">
<a name="24881463"></a>Pagani O, Regan MM, Walley BA, et al; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. <i>N Engl J Med.</i> 2014;371(2):107-118. doi:10.1056/NEJMoa1404037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/24881463/pubmed" id="24881463" target="_blank">24881463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18794551">
<a name="18794551"></a>Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. <i>J Clin Oncol</i>. 2008;26(30):4883-4890.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/18794551/pubmed" id="18794551" target="_blank">18794551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33538790">
<a name="33538790"></a>Reinisch M, Seiler S, Hauzenberger T, et al. Efficacy of endocrine therapy for the treatment of breast cancer in men: results from the MALE phase 2 randomized clinical trial. <i>JAMA Oncol.</i> 2021;7(4):565-572. doi:10.1001/jamaoncol.2020.7442<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/33538790/pubmed" id="33538790" target="_blank">33538790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21247627">
<a name="21247627"></a>van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. <i>Lancet</i>. 2011;377(9762):321-331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/21247627/pubmed" id="21247627" target="_blank">21247627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31479306">
<a name="31479306"></a>Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. <i>J Clin Oncol.</i> 2019;37(33):3152-3165. doi:10.1200/JCO.19.01472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/31479306/pubmed" id="31479306" target="_blank">31479306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25850534">
<a name="25850534"></a>Zagouri F, Sergentanis TN, Azim HA Jr, et al. Aromatase inhibitors in male breast cancer: a pooled analysis. <i>Breast Cancer Res Treat</i>. 2015;151(1):141-147. doi:10.1007/s10549-015-3356-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/25850534/pubmed" id="25850534" target="_blank">25850534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23722469">
<a name="23722469"></a>Zagouri F, Sergentanis TN, Koutoulidis V, et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. <i>Br J Cancer.</i> 2013;108(11):2259-2263. doi:10.1038/bjc.2013.255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exemestane-drug-information/abstract-text/23722469/pubmed" id="23722469" target="_blank">23722469</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8920 Version 253.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
